Tarsus (TARS) director Goodrich sells 2,954 shares in pre-planned trade

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. director Katherine Goodrich reported an open-market sale of Common Stock. She sold 2,954 shares on June 15, 2026 at a price of $62.08 per share. After this transaction, she directly holds 2,233 shares of Tarsus common stock.

The filing notes that this sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted by Goodrich on February 27, 2026, indicating the timing was set in advance rather than decided on the trade date.

Insights

Equity ownership & governance analyst

Director executes pre-planned share sale under 10b5-1 plan.

Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals common stock at $62.08 per share in an open-market transaction. Following the sale, she directly holds 2,233 shares, so this filing mainly updates her reported equity stake.

The footnote explains the sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 27, 2026. Such plans are set up in advance and execute based on pre-defined conditions, which generally makes the timing of trades less informative about the insider’s short-term view of the stock.

No derivative positions are listed in this filing, and there is no indication of additional option exercises or complex restructuring transactions. Overall, the event appears administrative and routine from a governance perspective, with limited implications for the broader investment case.

Insider Trade Summary 10b5-1

Net Seller: 2,954 shares ($183,384)

Net Sell 1 txn

Insider Goodrich Katherine

Role null

Sold 2,954 shs ($183K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,954	$62.08	$183K

Holdings After Transaction: Common Stock — 2,233 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,954 shares Sale price: $62.08 per share Shares after transaction: 2,233 shares +3 more

6 metrics

Shares sold 2,954 shares Open-market sale on June 15, 2026

Sale price $62.08 per share Price for Tarsus common stock in reported sale

Shares after transaction 2,233 shares Director’s direct holdings following the sale

Transaction code S (sale) Open-market or private sale of non-derivative common stock

Trading plan adoption date February 27, 2026 Date Rule 10b5-1 plan was adopted

Net share direction 2,954 net shares sold Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, non-derivative, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"transaction_type": "non-derivative""

net-sell financial

"netBuySellDirection": "net-sell""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodrich Katherine

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		S(1)		2,954	D	$62.08	2,233	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Tarsus Pharmaceuticals (TARS) disclose in this Form 4?

Tarsus Pharmaceuticals disclosed that director Katherine Goodrich sold 2,954 shares of common stock. The shares were sold in an open-market transaction at $62.08 per share, updating her reported ownership stake in the company after the sale.

Who is the insider involved in the latest Tarsus (TARS) Form 4 filing?

The insider is Katherine Goodrich, a director of Tarsus Pharmaceuticals. She reported a single open-market sale of 2,954 shares of the company’s common stock and now directly holds 2,233 shares following completion of that transaction.

How many Tarsus Pharmaceuticals (TARS) shares did the director sell and at what price?

Director Katherine Goodrich sold 2,954 shares of Tarsus Pharmaceuticals common stock. The sale was executed at a price of $62.08 per share in an open-market transaction dated June 15, 2026, as disclosed in the Form 4 filing.

How many Tarsus (TARS) shares does Katherine Goodrich hold after the reported sale?

After the reported open-market sale, director Katherine Goodrich directly holds 2,233 shares of Tarsus Pharmaceuticals common stock. This figure reflects her ownership immediately following the 2,954-share disposition reported in the Form 4 filing.

Was the Tarsus (TARS) insider sale carried out under a Rule 10b5-1 plan?

Yes. The filing states the sales were executed automatically under a Rule 10b5-1 trading plan. This plan was adopted by Katherine Goodrich on February 27, 2026, meaning the trade’s timing was pre-arranged rather than decided on the transaction date.

Does the Form 4 show any Tarsus (TARS) option exercises or derivative transactions?

No. The Form 4 reports only a non-derivative transaction involving common stock. It discloses an open-market sale of 2,954 common shares and shows no option exercises, warrant conversions, or other derivative security transactions in this filing.